PACS Stock Forecast & Price Target

PACS Group is supported by strong same-store fundamentals, with 3Q26 SNF revenue up 6.4% on occupancy of 91.3% and skilled mix of 29.5%, while revenue rose 11.5% year over year to $1.499 billion and adjusted EBITDA climbed 33.6% to $175.7 million. Its outlook is further strengthened by raised 2026 guidance to $5.95 billion-$6.05 billion of revenue and $685 million-$695 million of adjusted EBITDA, aided by quality incentive payments and improving payer mix, while operational quality remains high with 78.9% of rated SNF facilities at 4- or 5-Star. The company also has substantial growth runway from acquisitions, having added more than 8K net beds through 11/1, and its strong liquidity of $707.4 million plus net leverage of just 0.2x gives it flexibility to keep expanding and compounding earnings.

PACS Group is exposed to material reimbursement and policy risk, as potential Medicaid funding reforms and growing Medicare Advantage penetration could pressure skilled nursing margins, reduce funding for clinical staffing, and lower reimbursement versus Medicare fee-for-service. Its heavy geographic concentration in California adds another layer of vulnerability, since the state’s structurally higher occupancy and skilled mix may distort future KPI comparisons as the company expands beyond it. While tighter funding could accelerate industry M&A by forcing weaker operators to sell, that outcome does not offset the fundamental risk that future organic growth and same-facility improvement may be constrained.